Delu Wu
Xinyue Liu
Song Wang
Huanyu Zhang
Lina Wang- Department of Radiotherapy, The First Clinical Medical College of Lanzhou University, Lanzhou, Gansu, China
Peutz–Jeghers syndrome (PJS) is a rare autosomal dominant disorder characterized by mucocutaneous pigmentation (e.g., perioral melanotic macules) and gastrointestinal hamartomatous polyps, with heightened cancer susceptibility. This report describes a 34-year-old Han Chinese ethnicity woman with familial Peutz–Jeghers syndrome (PJS) and stage IIA HPV-independent gastric-type endocervical adenocarcinoma following bevacizumab therapy. Initial concurrent chemoradiation (paclitaxel with either nedaplatin or cisplatin with volumetric modulated arc therapy) achieved partial response, while subsequent maintenance therapy combining bevacizumab with chemotherapy induced complete radiographic remission. Crucially, progressive fading of pathognomonic perioral melanotic macules demonstrated temporal correlation with bevacizumab administration, with sustained remission at 1-year follow-up. These findings challenge the conventional paradigm of PJS pigmentation as a static feature by demonstrating that VEGF-mediated angiogenesis concurrently drives carcinogenesis and melanin deposition. The case highlights three key implications, namely: (1) validation of bevacizumab’s dual therapeutic potential against PJS-associated malignancies and cutaneous manifestations, (2) proposal of mucocutaneous pigmentation as a dynamic biomarker for treatment response monitoring, and (3) urgent need for prospective clinical trials evaluating VEGF inhibition in PJS through longitudinal surveillance of oncologic control and pigment dynamics.
Background
Peutz–Jeghers syndrome (PJS), a rare autosomal dominant genetic disorder, manifests pathognomonically through mucocutaneous pigmentation (particularly perioral melanotic macules) and the development of hamartomatous polyposis predominantly in the gastrointestinal tract. This condition carries significant oncogenic potential, with affected individuals demonstrating predisposition to various malignancies, particularly gastrointestinal carcinomas. We present a 34-year-old female proband with familial PJS who underwent multimodal therapy for cervical carcinoma. The patient initially received liposomal paclitaxel with nedaplatin as systemic chemotherapy, which was subsequently transitioned to a paclitaxel–cisplatin regimen administered concurrently with radiotherapy as part of definitive chemoradiation. This treatment approach achieved partial response, and the patient then began maintenance therapy combining bevacizumab with chemotherapy, which culminated in complete radiographic remission. Notably, the therapeutic intervention induced progressive attenuation of characteristic orofacial melanin deposition, with chronological correlation to bevacizumab administration. The treatment course exhibited favorable tolerability without significant adverse events. Mechanistically, bevacizumab—a recombinant humanized monoclonal antibody targeting vascular endothelial growth factor (VEGF)—mediates its anti-neoplastic effects through angiogenesis inhibition, a pathway increasingly recognized as potentially modifiable in PJS-related tumorigenesis. This observation suggests a dual therapeutic potential encompassing both neoplastic control and cutaneous manifestation amelioration in PJS patients.
Case presentation
A 34-year-old Han Chinese ethnicity female patient (Ms. Wu XX) was admitted to the Gastroenterology Department in June 2022 with a 6-month history of diarrhea and hematochezia. Her medical history included open abdominal surgery for intestinal obstruction at age 13. A physical examination revealed multiple perioral melanotic macules. The patient reported a family history of intestinal polyposis and perioral pigmentation in her father and children (see genetic pedigree in Figure 1). No other significant medical or familial history was noted.
Figure 1. Pedigree chart of a family with Peutz–Jeghers syndrome. Symbol key: Red symbols: Individuals exhibiting mucocutaneous pigmentation. Circles: Female family members. Squares: Male family members. Symbol with checkmark (✓): Index case (proband).
Imaging and endoscopic findings (June 2022):
Thoracic and abdominal CT:
Multiple intraluminal enhancing nodules in the gastric body (greater curvature), duodenum, pelvic small bowel, and ascending colon.
Endometrial thickening with heterogeneous myometrial enhancement (suspected fibroids).
Endoscopy:
Gastroscopy: Multiple gastric and duodenal polyps.
Colonoscopy: Small bowel polyposis (consistent with Peutz–Jeghers syndrome).
Histopathology (gastric biopsy):
Hyperplastic polyps with focal mild epithelial dysplasia.
Fundic gland polyps.
Clinical course:
December 2022: Re-admitted for abdominal distension. Repeat CT showed progression of duodenal, small bowel, and colonic polyps. Underwent enteroscopic polypectomy.
March 2023: Evaluated for recurrent diarrhea and hematochezia:
Tumor markers: CA-125: 123.00 U/mL, CA19-9: 462.00 U/mL, CA72-4: 8.60 U/mL.
Transvaginal ultrasound (Figure 2): Cervical mass, endometrial thickening, and uterine fibroids.
Figure 2. Histopathological findings of cervical cancer in a patient with Peutz–Jeghers syndrome. The tumor tissue exhibits irregular glandular and cribriform patterns, characterized by cells with large, hyperchromatic nuclei and abundant cytoplasm, demonstrating invasive growth.
Cervical biopsy: HPV-independent gastric-type endocervical adenocarcinoma (moderately differentiated).
Immunohistochemistry: ER (-), PR (-), PTEN (weak+), PAX-8 (focal+), Ki-67 (50% in hotspot areas), p53 (mutant pattern), CK7 (+), CK20 (-), p16 (patchy+).
Imaging staging:
PET/CT:
Hypermetabolic cervical lesion (right posterior wall) involving the posterior vaginal fornix (FIGO IIA).
Mild FDG uptake in duodenal, ileocecal, and colorectal polyps (consistent with PJS).
Post-polypectomy changes without residual hypermetabolism.
Pelvic MRI: Cervical cancer (T2b), Nabothian cysts, posterior uterine fibroid, and sigmoid polyps.
Endoscopic interventions (2023):
Gastroscopy: Numerous duodenal polyps (2.0–5.0 cm), with 5 large proximal polyps resected.
Colonoscopy: 12 polyps (>2 cm) removed from cecum to sigmoid colon.
Oncologic treatment:
April–May 2023: Received liposomal paclitaxel 200 mg + nedaplatin 120 mg (2 cycles).
June 2023: Volumetric modulated arc therapy (VMAT):
PTV50.4: 5040 cGy/28 fractions.
PGTVnd: 6020 cGy/28 fractions.
Intracavitary brachytherapy: HR-CTV 3000 cGy/5 fractions.
Concurrent chemotherapy (TP regimen):
Nab-paclitaxel 400 mg (d1) + cisplatin 30 mg (d1-3).
September 2023: Partial response (PR) on MRI.
October 2023: TP regimen + bevacizumab 500 mg (d1).
November 2023: Stable disease on MRI.
Follow-up (1 year):
Achieved complete response (CR) with no cervical recurrence.
Notable lightening of perioral pigmentation following polypectomy and bevacizumab therapy (Figure 3).
Figure 3. Comparative analysis of perioral melanotic macules in a Peutz–Jeghers syndrome patient before and after treatment.
Full therapeutic timeline documented (Figure 4).
Figure 4. Therapeutic timeline and radiographic evolution in a Peutz–Jeghers syndrome patient.
Unaffected individuals: Non-consanguineous family members showed no phenotypic abnormalities.
Diagnostic considerations:
The diagnosis of Peutz–Jeghers syndrome (PJS) was established based on clinical criteria, as genetic testing was not performed due to financial constraints. According to established diagnostic guidelines (1), PJS can be confirmed by meeting any of the following criteria:
1. Presence of two or more histologically confirmed Peutz–Jeghers-type hamartomatous polyps.
2. Any Peutz–Jeghers polyp in conjunction with a family history of PJS.
3. Characteristic mucocutaneous pigmentation (involving oral mucosa, lips, nasal mucosa, periorbital region, genitalia, or digits) with a positive family history of PJS.
4. Characteristic mucocutaneous pigmentation and any Peutz–Jeghers polyp.
Discussion
Peutz–Jeghers syndrome (PJS) is an autosomal dominant disorder with an estimated incidence ranging from 1:200,000 to 1:50,000 (2). The primary pathogenic mechanism involves loss-of-function mutations in the STK11/LKB1 gene, which disrupts multiple signaling pathways, including AMPK-mTOR, Wnt/β-catenin, and PI3K/AKT, leading to polyp formation and increased cancer susceptibility (1, 3, 4). STK11/LKB1 acts as a central regulator of cellular metabolism and proliferation. Its inactivation impairs AMPK-mediated inhibition of mTORC1, resulting in metabolic reprogramming characterized by enhanced glycolysis and lipid synthesis (the “Warburg effect”) to fuel tumor growth (5). Furthermore, STK11/LKB1 deficiency dysregulates the Hippo pathway by promoting nuclear translocation of YAP/TAZ, thereby activating pro-proliferative genes (e.g., CTGF, CYR61) and accelerating gastrointestinal polypogenesis (6). STK11/LKB1 loss also remodels the tumor microenvironment through PI3K/AKT–FOXO axis-mediated apoptosis suppression and aberrant activation of Wnt/β-catenin and Notch pathways, driving epithelial–mesenchymal transition (EMT) and cancer stemness (7, 8). Additionally, disruption of the LKB1–STRAD–MO25 complex compromises intestinal epithelial polarity via PAR1/MARK dysfunction, further impairing barrier integrity (9). Emerging evidence suggests that STK11/LKB1 modulates mitochondrial autophagy and ROS metabolism, forming a dynamic feedback loop with the p53–BAX apoptotic pathway (10, 11), which may explain the early-onset and multifocal malignancies in PJS. Collectively, these mechanisms reflect a triad of metabolic, polarity, and epigenetic dysregulation. Therapeutic strategies targeting the AMPK/mTOR–Hippo axis or combining epigenetic modifiers (e.g., HDAC inhibitors) may offer novel intervention opportunities (12).
Endoscopic polypectomy remains the cornerstone for managing gastrointestinal polyps in PJS. Balloon-assisted enteroscopy (BAE) has significantly reduced surgical needs, enabling the safe resection of polyps ≥1 cm to mitigate intussusception and obstruction risks, though repeated procedures are often required for complete small bowel surveillance (13, 14). Gastroscopy and colonoscopy effectively monitor and remove gastric/colorectal polyps with low complication rates (e.g., 0.25% perforation risk) (14). Surgery is reserved for complications (e.g., bowel necrosis, irreducible intussusception) or malignancies but may increase adhesion-related morbidity (13, 15).
Conventional approaches fail to prevent polyp recurrence or malignant transformation. PJS patients face a 37%–93% lifetime cancer risk, notably colorectal, breast, small intestinal, gastric, and pancreatic cancers (16). Recent studies focus on molecular mechanisms and targeted therapies for PJS-associated malignancies (Table 1). Cervical gastric-type adenocarcinoma (G-EAC), occurring in 11% of female PJS patients (17), exhibits aggressive behavior with early metastasis and poor response to conventional screening (TCT/HPV testing) (18). Treatment relies on surgery combined with chemoradiation and targeted therapies (Table 2), though outcomes remain inferior to HPV-related cervical cancer (19, 20). Preclinical studies explore mTOR inhibitors (e.g., everolimus), PARP inhibitors (e.g., olaparib), and AXL inhibitors (e.g., bemcentinib) to address STK11-related metabolic and DNA repair defects. Notably, combining bemcentinib with PD-1 inhibitors may overcome immunotherapy resistance in STK11-mutant tumors (20). Genetic counseling and preimplantation genetic testing (PGT) effectively prevent STK11 mutation transmission, with successful clinical applications reported (21). For mucocutaneous pigmentation, picosecond laser therapy shows promising cosmetic outcomes (22, 23).
Table 1. Pathogenic pathways and therapeutic targets in Peutz–Jeghers syndrome.
Table 2. Case reports of Peutz–Jeghers syndrome with gastric-type adenocarcinoma of the cervix (GAS).
The cervical adenocarcinoma in this case exhibited characteristic features of gastric-type adenocarcinoma (GAS), including HPV negativity and a distinctive immunohistochemical profile: ER (-), PR (-), PTEN (weak+), p53 (mutant pattern), CDX-2 (-), SATB2 (-), villin (-), CK7 (+), CK20 (-), VIM (-), and p16 (patchy+). These findings are consistent with PJS-associated cervical cancer. For limited-stage cervical cancer (IIA2), concurrent chemoradiation (IMRT + cisplatin) remains the standard treatment. However, for GAS-type cervical cancer, the TP regimen (paclitaxel + platinum) is often preferred. Bevacizumab, a monoclonal antibody targeting VEGF, inhibits tumor angiogenesis and is approved for cervical and colorectal cancers. In this case, the addition of bevacizumab to the TP regimen resulted in tumor regression and a complete response (CR), suggesting its potential efficacy in PJS-associated cervical cancer.
The mucocutaneous pigmentation in PJS is primarily caused by localized melanin deposition and dermal vascular proliferation, linked to AMPK/mTOR signaling dysregulation due to STK11/LKB1 inactivation. STK11 mutations activate the mTOR pathway, upregulating HIF-1α and VEGF expression, which stimulates angiogenesis and melanocyte activity (43, 44). VEGF not only promotes tumor angiogenesis but also induces melanocyte proliferation and migration through paracrine signaling (45). Thus, the pigmentation may reflect the systemic activation of the VEGF/mTOR pathway rather than being merely a cutaneous manifestation. Bevacizumab, by inhibiting VEGF and its downstream signaling (e.g., PI3K/AKT/mTOR) (46), may reduce melanocyte activity and melanin deposition, leading to pigmentation regression. Although this phenomenon has not been widely reported in PJS patients, this case suggests that VEGF signaling may play a significant role in the pathogenesis of mucocutaneous pigmentation in PJS. Furthermore, whether pigmentation changes can serve as a biomarker for treatment response in PJS warrants further investigation.
Future perspectives and therapeutic potential
Our study reveals that the VEGF/PI3K/AKT/mTOR signaling axis may concurrently regulate both carcinogenesis and melanin deposition in the pathogenesis of PJS, opening promising avenues to develop novel therapeutic strategies. Beyond conventional synthetic inhibitors, several natural compounds have demonstrated efficacy in modulating these key signaling pathways and warrant further investigation. Notable candidates include conjugated linoleic acid, recognized for its health-promoting properties, and epigallocatechin-3-gallate—the predominant polyphenol in green tea—which not only effectively suppresses PI3K/AKT/mTOR signaling and VEGF expression but also exhibits synergistic effects with chemotherapeutic agents in preclinical studies (47). Although we propose a mechanism whereby bevacizumab may ameliorate cutaneous hyperpigmentation by inhibiting VEGF-driven melanocyte activity—a hypothesis physiologically plausible and supported by our clinical observations—it must be emphasized that this association remains correlative and requires further validation. Our study currently lacks direct histopathological evidence, including comparative analyses of melanin content, melanocyte density, and CD31-stained microvessel density in lesions before and after treatment as well as biochemical quantification of local VEGF levels. Therefore, the inferred causal relationship should be interpreted with caution. Building on these findings, future research should establish STK11-deficient models to systematically evaluate the efficacy of natural compounds in reducing mucocutaneous pigmentation and suppressing hamartomatous polyp growth while simultaneously addressing the evidence gaps in our current study. Specifically, pre- and post-intervention histopathological analyses of model lesions—quantifying changes in melanin content, melanocyte density, microvessel density, and local VEGF levels—would provide direct evidence for the proposed mechanism. Further clinical investigations could explore the potential of natural compounds as adjuncts to targeted therapies such as bevacizumab, employing multidimensional assessments to validate synergistic effects. This approach aims to enhance therapeutic efficacy, reduce dosage requirements, minimize adverse effects, and ultimately improve long-term outcomes for PJS patients.
Author’s note
Bevacizumab is a registered trademark of Qilu Pharmaceutical Co., LTD; however, no financial or promotional relationships exist between the authors and any commercial entity associated with this drug.
Data availability statement
The original contributions presented in the study are included in the article/Supplementary Material. Further inquiries can be directed to the corresponding author.
Ethics statement
Written informed consent was obtained from the individual(s) for the publication of any potentially identifiable images or data included in this article.
Author contributions
DW: Writing – original draft. XL: Data curation, Methodology, Writing – review & editing. SW: Data curation, Methodology, Writing – review & editing. GQ: Methodology, Writing – review & editing. HZ: Methodology, Writing – review & editing. LW: Funding acquisition, Methodology, Resources, Writing – review & editing.
Funding
The author(s) declared that financial support was received for this work and/or its publication. This study was supported by National Natural Science Foundation of China (Grant No. 82060553) and Natural Science Foundation of Gansu Province (Grant No. 25JRRA557).
Acknowledgments
The authors acknowledge the multidisciplinary oncology team at the First Clinical Medical College of Lanzhou University for their collaborative efforts in patient care. Special gratitude is extended to the patient for her cooperation and consent to share this clinical experience.
Conflict of interest
The author(s) declared that this work was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Generative AI statement
The author(s) declared that generative AI was not used in the creation of this manuscript.
Any alternative text (alt text) provided alongside figures in this article has been generated by Frontiers with the support of artificial intelligence and reasonable efforts have been made to ensure accuracy, including review by the authors wherever possible. If you identify any issues, please contact us.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Abbreviations
PJS, Peutz–Jeghers syndrome; VEGF, vascular endothelial growth factor; TP, paclitaxel + cisplatin (chemotherapy regimen); CR, complete response; PR, partial response; BAE, balloon-assisted enteroscopy; VMAT, volumetric modulated arc therapy; IMRT, intensity-modulated radiation therapy; HR-CTV, high-risk clinical target volume; PGTVnd, planning gross tumor volume for nodal disease; NACT, neoadjuvant chemotherapy; RH, radical hysterectomy; ACT, adjuvant chemotherapy; CCRT, concurrent chemoradiation therapy; IHC, immunohistochemistry; G-EAC, gastric-type endocervical adenocarcinoma; FIGO, International Federation of Gynecology and Obstetrics; NED, no evidence of disease; EMT, epithelial–mesenchymal transition; ROS, reactive oxygen species; AMPK, adenosine monophosphate-activated protein kinase; mTOR, mechanistic target of rapamycin; PI3K/AKT, phosphatidylinositol 3-kinase/protein kinase B; HIF-1α, hypoxia-inducible factor 1-alpha; PARP, poly (ADP-ribose) polymerase; PD-1, programmed cell death protein 1; PGT, preimplantation genetic testing; CT, computed tomography; MRI, magnetic resonance imaging; PET/CT, positron emission tomography/computed tomography; FDG, fluorodeoxyglucose; CK7/CK20, cytokeratin 7/cytokeratin 20; ER/PR, estrogen receptor/progesterone receptor; HDAC, histone deacetylase.
References
1. Beggs AD, Latchford AR, Vasen HF, Moslein G, Alonso A, Aretz S, et al. Peutz-Jeghers syndrome: a systematic review and recommendations for management. Gut. (2010) 59:975–86. doi: 10.1136/gut.2009.198499
2. Giardiello FM and Trimbath JD. Peutz-Jeghers syndrome and management recommendations. Clin Gastroenterol Hepatol. (2006) 4:408–15. doi: 10.1016/j.cgh.2005.11.005
3. Hsieh MJ, Weng CC, Lin YC, Wu CC, Chen LT, and Cheng KH. Inhibition of β-catenin activity abolishes LKB1 loss-driven pancreatic cystadenoma in mice. Int J Mol Sci. (2021) 22:4649. doi: 10.3390/ijms22094649
4. Glaviano A, Foo ASC, Lam HY, Yap KCH, Jacot W, Jones RH, et al. PI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancer. Mol Cancer. (2023) 22:138. doi: 10.1186/s12943-023-01827-6
5. Shackelford DB and Shaw RJ. The LKB1-AMPK pathway: metabolism and growth control in tumour suppression. Nat Rev Cancer. (2009) 9:563–75. doi: 10.1038/nrc2676
6. Mohseni M, Sun J, Lau A, Curtis S, Goldsmith J, Fox VL, et al. A genetic screen identifies an LKB1-MARK signalling axis controlling the Hippo-YAP pathway. Nat Cell Biol. (2014) 16:108–17. doi: 10.1038/ncb2884
7. Ji H, Ramsey MR, Hayes DN, Fan C, McNamara K, Kozlowski P, et al. LKB1 modulates lung cancer differentiation and metastasis. Nature. (2007) 448:807–10. doi: 10.1038/nature06030
8. Ollila S and Mäkelä TP. The tumor suppressor kinase LKB1: lessons from mouse models. J Mol Cell Biol. (2011) 3:330–40. doi: 10.1093/jmcb/mjr016
9. Xia T, Chen D, Liu X, Qi H, Wang W, Chen H, et al. Midkine noncanonically suppresses AMPK activation through disrupting the LKB1-STRAD-Mo25 complex. Cell Death Dis. (2022) 13:414. doi: 10.1038/s41419-022-04801-0
10. Choi EJ, Oh HT, Lee SH, Zhang CS, Li M, Kim SY, et al. Metabolic stress induces a double-positive feedback loop between AMPK and SQSTM1/p62 conferring dual activation of AMPK and NFE2L2/NRF2 to synergize antioxidant defense. Autophagy. (2024) 20:2490–510. doi: 10.1080/15548627.2024.2374692
11. Feng Y, Chen Y, Wu X, Chen J, Zhou Q, Liu B, et al. Interplay of energy metabolism and autophagy. Autophagy. (2024) 20:4–14. doi: 10.1080/15548627.2023.2247300
12. Cheng B, Pan W, Xiao Y, Ding Z, Zhou Y, Fei X, et al. HDAC-targeting epigenetic modulators for cancer immunotherapy. Eur J Med Chem. (2024) 265:116129. doi: 10.1016/j.ejmech.2024.116129
13. Dai YC, Xiao B, Zhang YL, Zhi FC, Jiang B, and Zhou DY. Endoscopic and Surgical Treatment of 52 Cases of Peutz-Jeghers Syndrome. Journal of Clinical Internal Medicine. (2005) 22:455–7. doi: 10.3969/j.issn.1001-9057.2005.07.009
14. Zhu HY and Du YQ. Progress in Small Bowel Endoscopy Treatment for Peutz-Jeghers Syndrome. Journal of Colorectal & Anal Surgery. (2023) 29:122–6. doi: 10.19668/j.cnki.issn1674-0491.2023.02.004
15. Luo MW, Zhang ZQ, Wei Y, Yan WD, and Yan DW. A Case Report of Peutz-Jeghers Syndrome Complicated with Jejunal Intussusception Obstruction. Journal of Shanghai Jiaotong University (Medical Science). (2021) 41:1129–32. doi: 10.3969/j.issn.1674-8115.2021.08.023
16. van Lier MG, Wagner A, Mathus-Vliegen EM, Kuipers EJ, Steyerberg EW, and van Leerdam ME. High cancer risk in Peutz-Jeghers syndrome: a systematic review and surveillance recommendations. Am J Gastroenterol. (2010) 105:1258–64. doi: 10.1038/ajg.2009.725
17. Li X, Qi Y, Zhang W, Rao Y, Zhang N, and Qu P. Peutz-Jeghers syndrome with gastric-type mucinous endocervical adenocarcinoma and sex-cord tumor with annular tubules: A case report. Front Med (Lausanne). (2023) 10:1094839. doi: 10.3389/fmed.2023.1094839
18. Karamurzin YS, Kiyokawa T, Parkash V, Jotwani AR, Patel P, Pike MC, et al. Gastric-type endocervical adenocarcinoma: an aggressive tumor with unusual metastatic patterns and poor prognosis. Am J Surg Pathol. (2015) 39:1449–57. doi: 10.1097/PAS.0000000000000532
19. Wang WL and Ye H. Research Progress on Peutz-Jeghers Syndrome-Associated Gastric-Type Adenocarcinoma of the Cervix. Chinese Journal of Minimally Invasive Surgery. (2022) 2:167–9. doi: 10.3969/j.issn.1009-6604.2022.02.014
20. Jiang AQ, Kang Y, and Xu CJ. Research Progress on Peutz-Jeghers Syndrome-Associated Gastric-Type Adenocarcinoma of the Cervix. Chinese Journal of Practical Gynecology and Obstetrics. (2023) 39:1144–8. doi: 10.19538/j.fk2023110118
21. Byrjalsen A, Roos L, Diemer T, Karstensen JG, Løssl K, and Jelsig AM. Preimplantation genetic testing in two Danish couples affected by Peutz-Jeghers syndrome. Scand J Gastroenterol. (2023) 58:314–8. doi: 10.1080/00365521.2022.2129031
22. Zeng R, Wu Q, Guo L, and Lin T. Successful treatment of oral pigmented spots in Chinese subjects with Peutz-Jeghers syndrome using a 755-nm picosecond laser. Indian J Dermatol Venereol Leprol. (2021) 87:288–9. doi: 10.25259/IJDVL_151_20
23. Agud-Dios M, Perandones-Gonzalez H, Fernández-Domper L, Dominguez Santas M, and Boixeda de Miquel P. Picosecond 755-nm alexandrite laser treatment for oral lentiginosis in Peutz-Jeghers disease. Lasers Surg Med. (2022) 54:823–4. doi: 10.1002/lsm.23553
24. Gwinn DM, Shackelford DB, Egan DF, Mihaylova MM, Mery A, Vasquez DS, et al. AMPK phosphorylation of raptor mediates a metabolic checkpoint. Mol Cell. (2008) 30:214–26. doi: 10.1016/j.molcel.2008.03.003
25. Lo B, Strasser G, Sagolla M, Austin CD, Junttila M, and Mellman I. Lkb1 regulates organogenesis and early oncogenesis along AMPK-dependent and -independent pathways. J Cell Biol. (2012) 199:1117–30. doi: 10.1083/jcb.201208080
26. Partanen JI, Tervonen TA, and Klefström J. Breaking the epithelial polarity barrier in cancer: the strange case of LKB1/PAR-4. Philos Trans R Soc Lond B Biol Sci. (2013) 368:20130111. doi: 10.1098/rstb.2013.0111
27. Chan KT, Asokan SB, King SJ, Bo T, Dubose ES, Liu W, et al. LKB1 loss in melanoma disrupts directional migration toward extracellular matrix cues. J Cell Biol. (2014) 207:299–315. doi: 10.1083/jcb.201404067
28. Ylikorkala A, Rossi DJ, Korsisaari N, Luukko K, Alitalo K, Henkemeyer M, et al. Vascular abnormalities and deregulation of VEGF in Lkb1-deficient mice. Science. (2001) 293:1323–6. doi: 10.1126/science.1062074
29. Brugarolas J and Kaelin WG Jr. Dysregulation of HIF and VEGF is a unifying feature of the familial hamartoma syndromes. Cancer Cell. (2004) 6:7–10. doi: 10.1016/j.ccr.2004.06.020
30. Faubert B, Vincent EE, Griss T, Samborska B, Izreig S, Svensson RU, et al. Loss of the tumor suppressor LKB1 promotes metabolic reprogramming of cancer cells via HIF-1α. Proc Natl Acad Sci U S A. (2014) 111:2554–9. doi: 10.1073/pnas.1312570111
31. Della Corte CM, Ciaramella V, Di Mauro C, Castellone MD, Papaccio F, Fasano M, et al. Metformin increases antitumor activity of MEK inhibitors through GLI1 downregulation in LKB1 positive human NSCLC cancer cells. Oncotarget. (2016) 7:4265–78. doi: 10.18632/oncotarget.6559
32. Zinatizadeh MR, Miri SR, Zarandi PK, Chalbatani GM, Rapôso C, Mirzaei HR, et al. The Hippo Tumor Suppressor Pathway (YAP/TAZ/TEAD/MST/LATS) and EGFR-RAS-RAF-MEK in cancer metastasis. Genes Dis. (2021) 8:48–60. doi: 10.1016/j.gendis.2019.11.003
33. Wang Y, Liu J, Zheng S, Cao L, Li Y, and Sheng R. The deubiquitinase USP10 mediates crosstalk between the LKB1/AMPK axis and Wnt/β-catenin signaling in cancer. FEBS Lett. (2023) 597:3061–71. doi: 10.1002/1873-3468.14763
34. Tong T, Fan Q, Shi S, Li Y, and Wang Y. Gastric-type mucinous adenocarcinoma of the cervix in a woman with Peutz-Jeghers syndrome: a case report. Acta Chir Belg. (2023) 123:448–53. doi: 10.1080/00015458.2022.2040110
35. Vu Dinh G, Doan Thi Hong N, Vo Ngoc T, Nguyen Thanh L, Hoang Thi H, and Phung Thi H. Peuzt - Jeghers syndrome with gastric type mucinous endocervical adenocarcinoma in a young woman: A case report. Ann Med Surg (Lond). (2021) 69:102700. doi: 10.1016/j.amsu.2021.102700
36. Wu X, Liang D, and He Y. Peutz Jeghers syndrome accompanied with cervical gastric adenocarcinoma and extensive metastasis: a case report. Int J Clin Exp Pathol. (2023) 16:386–92.
37. Kotaka S, Kanno K, Yanai S, Omori M, and Andou M. Peutz-Jeghers syndrome complicated by gastric-type cervical mucinous carcinoma and primary peritoneal carcinoma. J Obstet Gynaecol Res. (2021) 47:3732–6. doi: 10.1111/jog.14944
38. Kim Y, Kim EY, Kim TJ, Lim KT, Lee KH, Chun Y, et al. A rare case of gastric-type mucinous adenocarcinoma in a woman with Peutz-Jeghers syndrome. Obstet Gynecol Sci. (2019) 62:474–7. doi: 10.5468/ogs.2019.62.6.474
39. Neyaz A, Husain N, Deodhar M, Khurana R, Shukla S, and Arora A. Synchronous cervical minimal deviation adenocarcinoma, gastric type adenocarcinoma and lobular endocervical glandular hyperplasia along with STIL in peutz-jeghers syndrome: eliciting oncogenesis pathways. Turk Patoloji Derg. (2019) 35:247–53. doi: 10.5146/tjpath.2017.01406
40. Yang L, Duan D, Xiong Y, Liu T, Zhao L, Lai F, et al. Preoperative multimodal ultrasonic imaging in a case of Peutz-Jeghers syndrome complicated by atypical lobular endocervical glandular hyperplasia: a case report and literature review. Hered Cancer Clin Pract. (2024) 22:3. doi: 10.1186/s13053-024-00275-7
41. Peng WX, Kure S, Ishino K, Kurose K, Yoneyama K, Wada R, et al. P16-positive continuous minimal deviation adenocarcinoma and gastric type adenocarcinoma in a patient with Peutz-Jeghers syndrome. Int J Clin Exp Pathol. (2015) 8:5877–82.
42. Zhou Y, Wang X, Li Y, Zhang W, Xu X, Pang Y, et al. When synchronous mucinous metaplasia and neoplasia of the female genital tract and peutz-jeghers syndrome meet: a case report and literature reviews. BMC Womens Health. (2024) 24:375. doi: 10.1186/s12905-024-03184-y
43. Amin RM, Hiroshima K, Miyagi Y, Kokubo T, Hoshi K, Fujisawa T, et al. Role of the PI3K/Akt, mTOR, and STK11/LKB1 pathways in the tumorigenesis of sclerosing hemangioma of the lung. Pathol Int. (2008) 58:38–44. doi: 10.1111/j.1440-1827.2007.02186.x
44. Shackelford DB, Vasquez DS, Corbeil J, Wu S, Leblanc M, Wu CL, et al. mTOR and HIF-1alpha-mediated tumor metabolism in an LKB1 mouse model of Peutz-Jeghers syndrome. Proc Natl Acad Sci U S A. (2009) 106:11137–42. doi: 10.1073/pnas.0900465106
45. Parikh R, Parikh S, Berzin D, Vaknine H, Ovadia S, Likonen D, et al. Recycled melanoma-secreted melanosomes regulate tumor-associated macrophage diversification. EMBO J. (2024) 43:3553–86. doi: 10.1038/s44318-024-00103-7
46. Rho SB, Byun HJ, Kim BR, and Lee CH. LKB1/STK11 tumor suppressor reduces angiogenesis by directly interacting with VEGFR2 in tumorigenesis. Biomol Ther (Seoul). (2023) 31:456–65. doi: 10.4062/biomolther.2023.106
47. Javedan G, Shidfar F, Davoodi SH, Ajami M, Gorjipour F, Sureda A, et al. Conjugated linoleic acid rat pretreatment reduces renal damage in ischemia/reperfusion injury: Unraveling antiapoptotic mechanisms and regulation of phosphorylated mammalian target of rapamycin. Mol Nutr Food Res. (2016) 60:2665–77. doi: 10.1002/mnfr.201600112
Keywords: Peutz-Jeghers syndrome, gastric-type endocervical adenocarcinoma, labial melanotic macules, bevacizumab, chemoradiation
Citation: Wu D, Liu X, Wang S, Zhang H, Qu G and Wang L (2026) A novel effect of bevacizumab in reducing characteristic pigmentation in Peutz–Jeghers syndrome: a case report and literature review. Front. Oncol. 15:1694187. doi: 10.3389/fonc.2025.1694187
Received: 28 August 2025; Accepted: 08 December 2025; Revised: 23 November 2025;
Published: 07 January 2026.
Edited by:
Anton A. Buzdin, European Organisation for Research and Treatment of Cancer, BelgiumReviewed by:
Hamidreza Pazoki-Toroudi, Iran University of Medical Sciences, IranStefano Sol, Massachusetts General Hospital, United States
Copyright © 2026 Wu, Liu, Wang, Zhang, Qu and Wang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Lina Wang, d2FuZ2xuMThAbHp1LmVkdS5jbg==